Mining gene expression profiles: Expression signatures as cancer phenotypes

Nature Reviews Genetics

Volumn 8, Issue 8, 2007, Pages 601-609

  Nevins, Joseph R ^a   Potti, Anil ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; RAPAMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEUPLOIDY; BIOLOGICAL TRAIT; BIOLOGY; CANCER CELL CULTURE; CHROMOSOMAL INSTABILITY; CLINICAL FEATURE; DNA SEQUENCE; DRUG SENSITIVITY; FEASIBILITY STUDY; GENE CLUSTER; GENE EXPRESSION; GENE IDENTIFICATION; GENE MAPPING; GENETIC ANALYSIS; HUMAN; IN VIVO STUDY; LINKAGE ANALYSIS; MICROARRAY ANALYSIS; ONCOGENE MYC; ONCOGENE SRC; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW; STRATIFICATION; THERAPY EFFECT; VALIDATION THERAPY;

CELL LINE, TUMOR; CHROMOSOMAL INSTABILITY; DATA INTERPRETATION, STATISTICAL; DATABASES, GENETIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; PHENOTYPE;

EID: 34447555782     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg2137     Document Type: Review

References (67)

1. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999). The paradigm for use of both unsupervised and supervised methods of gene expression analysis to define new classes of tumours and predict these classes in new samples.
2. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
3. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
4. Rhodes, D. R. et al. Mining for regulatory programs in the cancer transcriptome. Nature Genet. 37, 579-583 (2005).
5. Rhodes, D. R. & Chinnaiyan, A. M. Integrative analysis of the cancer transcriptome. Nature Genet. 37, S31-S37 (2005).
6. Rhodes, D. R. et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl Acad. Sci. USA 101, 9309-9314 (2004).
7. Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863-14868 (1998).
8. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
9. Perou, C. M. et al. Molecular portraits of human breast tumors. Nature 406, 747-752 (2000).
10. Ramaswamy, S. et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sci. USA 98, 15149-15154 (2001).
11. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811-816 (2004).
12. Hayes, D. N. et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol. 24, 5079-5090 (2006).
13. Dave, S. S. et al. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med. 354, 2431-2442 (2006).
14. Dave, S. S. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159-2169 (2004).
15. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005).
16. Yanaihara, N. et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189-198 (2006).
17. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
18. Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070 (2005).
19. Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257-2261 (2006).
20. Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nature Rev. Cancer 6, 857-866 (2006).
21. Ramaswamy, S., Ross, K. N., Lander, E. S. & Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nature Genet. 33, 59-54 (2003).
22. Berchuck, A. et al. Patterns of gene expression that characterize long term survival in advanced serous ovarian cancers. Clin. Cancer Res. 11, 3686-3696 (2005).
23. Beer, D. G. et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Med. 8, 816-824 (2002).
24. Potti, A. et al. A genomic strategy to refine prognosis in non-small cell lung carcinoma. N. Engl. J. Med. 355, 570-580 (2006).
25. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
26. Huang, E. et al. Gene expression predictors of breast cancer outcomes. Lancet 361, 1590-1596 (2003).
27. Shipp, M. A. et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med. 8, 68-74 (2002).
28. Pomeroy, S. L. et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442 (2002).
29. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
30. van'T Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002). The initial example of a gene expression profile developed to refine and improve clinical prognosis.
31. Singh, D. et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209 (2002).
32. Pittman, J. et al. Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc. Natl Acad. Sci. USA 101, 8431-8436 (2004).
33. West, M. et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl Acad. Sci. USA 98, 11462-11467 (2001).
34. Ein-Dor, L., Kela, I., Getz, G., Givol, D. & Domany, E. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21, 171-178 (2005).
35. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005). A description of GSEA methodology as a tool to identify biological context in gene expression profiles.
36. Segal, E., Friedman, N., Koller, D. & Regev, A. A module map showing conditional activity of expression modules in cancer. Nature Genet. 36, 1090-1098 (2004).
37. Lamb, J. et al. The Connectivity Map: using gene expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006). A description of a novel approach to connect two biological states, using gene expression as the intermediary.
38. Wei, G. et al. Gene expression based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10, 331-342 (2006).
39. Hieronymus, H. et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10, 321-330 (2006).
40. Desai, K. V. et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc. Natl Acad. Sci. USA 99, 6967-6972 (2002).
41. Ferrando, A. A. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75-87 (2002).
42. Huang, E. et al. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nature Genet. 34, 226-230 (2003).
43. Black, E. P. et al. Distinct gene expression phenotypes of cells lacking RB and RB family members. Cancer Res. 63, 3716-3723 (2003).
44. Sweet-Cordero, A. et al. An oncogenic KRAS2 expression signature identified by cross-species gene expression analysis. Nature Genet. 37, 48-54 (2005).
45. Bild, A. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006). The development of gene expression signatures that reflect the activation or deregulation of various oncogenic signalling pathways, together with the utilization of these signatures to predict sensitivity to drugs that target the pathways.
46. Lamb, J. et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114, 323-334 (2003).
47. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 17, 671-674 (1990). The first comprehensive description of genetic events involved in colon carcinogenesis.
48. Dressman, H. K. et al. An integrated genomic-based approach to individualized treatment of patients with advanced stage ovarian cancer. J. Clin. Oncol. 25, 517-525 (2007).
49. Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 274-275 (2006).
50. Chang, J. C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
51. Ayers, M. et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22, 2284-2293 (2004).
52. Huang, F. et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 67, 2226-2238 (2007).
53. Coldren, C. D. et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol. Cancer Res. 4, 521-528 (2006).
54. Balko, J. M. et al. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics 7, 289 (2006).
55. Staunton, J. E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA 98, 10787-19792 (2001).
56. Potti, A. et al. A genomic strategy to guide the use of chemotherapeutic drugs in solid tumors. Nature Med. 12, 1294-1300 (2006).
57. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nature Genet. 38, 973-974 (2006).
58. Chang, H. Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2, 206-214 (2004).
59. Adler, A. S. et al. Genetic regulators of large-scale transcriptional signatures in cancer. Nature Genet. 38, 421-430 (2006). A demonstration of the use of an expression signature as a cancer phenotype in a genetic association study to identify chromosomal alterations that associate with the phenotype.
60. Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122 (2005).
61. Fan, C. et al. Different gene expression based predictors for breast cancer patients are concordant. N. Engl. J. Med. 355, 560-569 (2006).
62. The MicroArray Quality Control Consortium. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nature Biotechnol. 24, 1151-1161 (2006).
63. Chang, H. Y. et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102, 3738-3743 (2005).
64. Davies, H. et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65, 7591-7595 (2005).
65. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
66. Parsons, D. W. et al. Colorectal cancer: mutations in a signalling pathway. Nature 436, 792 (2005).
67. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).